Comprehensive Review
K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review

https://doi.org/10.3816/CLC.2006.n.030Get rights and content

Abstract

The Ras proteins are pivotal regulators of cellular proliferation, differentiation, motility, and apoptosis. Mutations on the K-ras gene have been found in 20%–30% of non–small-cell lung cancers and are believed to play a key role in this malignancy. Herein, we review the complex biochemical mechanisms through which K-ras exerts its cellular effects and the results from studies designed to evaluate the clinical importance of K-ras in patients with lung cancer. Since the demonstration of K-ras mutation as a negative prognostic marker 2 decades ago, 8 studies have supported this finding, but an equal number have failed to confirm this. There are also conflicting data for K-ras as a predictor of resistance to chemotherapy and radiation therapy. Progress has been hampered by relatively small studies, different methods of molecular analysis, and heterogeneity in histologic subtypes, stage, treatment administered, and survival criteria used. However, recent findings among patients treated with adjuvant chemotherapy or epidermal growth factor receptor inhibitors highlight that K-ras might yet be an important biomarker for non–small-cell lung cancer and worthy of further research.

References (89)

  • C Guerra et al.

    Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context

    Cancer Cell

    (2003)
  • CF Kim et al.

    Identification of bronchioalveolar stem cells in normal lung and lung cancer

    Cell

    (2005)
  • A Berns

    Stem cells for lung cancer?

    Cell

    (2005)
  • JL Ramirez et al.

    Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients

    Cancer Lett

    (2003)
  • F Grossi et al.

    Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers

    Eur J Cancer

    (2003)
  • MD Brundage et al.

    Prognostic factors in non-small cell lung cancer: a decade of progress

    Chest

    (2002)
  • C Camps et al.

    Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer?

    Lung Cancer

    (2005)
  • HA Wakelee et al.

    Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIA non-small cell lung cancer (NSCLC) does not increase the expected risk of death from intercurrent disease (DID) in eastern cooperative oncology group (ECOG) trial E3590

    Lung Cancer

    (2005)
  • AD Cox et al.

    The dark side of ras: regulation of apoptosis

    Oncogene

    (2003)
  • AA Adjei

    Blocking oncogenic ras signaling for cancer therapy

    J Natl Cancer Inst

    (2001)
  • JF Hancock et al.

    Ras plasma membrane signalling platforms

    Biochem J

    (2005)
  • A Mor et al.

    Compartmentalized ras/mapk signaling

    Annu Rev Immunol

    (2006)
  • J Downward

    Targeting RAS signalling pathways in cancer therapy

    Nat Rev Cancer

    (2003)
  • DA Cantrell

    GTPases and T cell activation

    Immunol Rev

    (2003)
  • TK Schlesinger et al.

    The TAO of MEKK

    Front Biosci

    (1998)
  • A Kauffmann-Zeh et al.

    Suppression of c-myc-induced apoptosis by ras signalling through PI(3)K and PKB

    Nature

    (1997)
  • M Tsuneoka et al.

    Ras/MEK signaling suppresses myc-dependent apoptosis in cells transformed by c-myc and activated ras

    Oncogene

    (2000)
  • T Joneson et al.

    Suppression of ras-induced apoptosis by the rac GTPase

    Mol Cell Biol

    (1999)
  • JA Fresno Vara et al.

    PI3K/Akt signalling pathway and cancer

    Cancer Treat Rev

    (2004)
  • D Morgensztern et al.

    PI3K/Akt/mTOR pathway as a target for cancer therapy

    Anticancer Drugs

    (2005)
  • MW Mayo et al.

    The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance

    Biochim Biophys Acta

    (2000)
  • M Karin et al.

    NF-kappaB in cancer: from innocent bystander to major culprit

    Nat Rev Cancer

    (2002)
  • C Nakanishi et al.

    Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs

    Nat Rev Cancer

    (2005)
  • M Dajee et al.

    NF-kappaB blockade and oncogenic ras trigger invasive human epidermal neoplasia

    Nature

    (2003)
  • R Dammann et al.

    Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3

    Nat Genet

    (2000)
  • L Shivakumar et al.

    The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation

    Mol Cell Biol

    (2002)
  • K Kinbara et al.

    Ras GTPases: integrins' friends or foes?

    Nat Rev Mol Cell Biol

    (2003)
  • J Rak et al.

    Oncogenes as inducers of tumor angiogenesis

    Cancer Metastasis Rev

    (1995)
  • J Rak et al.

    Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis

    Cancer Res

    (1995)
  • T Konishi et al.

    The K-ras gene regulates vascular endothelial growth factor gene expression in non-small cell lung cancers

    Int J Oncol

    (2000)
  • YH Kang et al.

    The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer

    J Korean Med Sci

    (2001)
  • X Zhang et al.

    Regulation of vascular endothelial growth factor by the wnt and K-ras pathways in colonic neoplasia

    Cancer Res

    (2001)
  • T Mukhopadhyay et al.

    Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA

    Cancer Res

    (1991)
  • R Alemany et al.

    Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells

    Cancer Gene Ther

    (1996)
  • Cited by (200)

    • KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)

      2021, Lung Cancer
      Citation Excerpt :

      The transversion mutations G12C and G12 V (substituting a pyrimidine for a purine or vice versa) are more prevalent in smokers, while the transition mutations G12D and G12S (substituting purine for purine or pyrimidine for pyrimidine) are more prevalent in never-smokers [reviewed in 8,13]. Contradictory results on the prognostic value of KRAS mutations in NSCLC have been published [8,14,15] and similarly, the association of different KRAS mutation subtypes with clinical outcomes remains unclear [16]. The published results on the prognostic value of KRAS G12C mutations also vary greatly, probably due to different inclusion criteria and methodologies: a small, retrospective study in routine care in China reported better progression-free-survival (PFS) for patients with advanced NSCLC and KRAS G12C mutations, compared to non-G12C mutations [17].

    • An Unusual Presentation of Aggressive Primary Invasive Adenocarcinoma of Lung

      2021, American Journal of the Medical Sciences
      Citation Excerpt :

      Further studies should be done to unveil the reason behind gender differences in NSCLC with EGFR mutations. Kirsten rat sarcoma (KRAS) gene mutations can be present in approximately 15 to 25 percent of lung adenocarcinomas.21 In patients with KRAS-mutated NSCLC, programmed cell death ligand 1 (PD-L1) expression (44 percent) was reportedly higher in patients with smoking history versus former (20 percent) or never smokers (13 percent).18

    View all citing articles on Scopus

    Electronic forwarding or copying is a violation of US and International Copyright Laws.

    Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.

    View full text